Show Search Form

Search Results

registered interest	true false
date	exactly: or between: and
answering body
answering dept id
answering dept short name
answering dept sort name
hansard heading
house id
legislature	pref label
question text
tabling member constituency
tabling member printed
uin
answer	is ministerial correction true false date of answer exactly: or between: and answer text answering member constituency answering member printed grouped question UIN question first answered answering member label attachment file name title
tabling member	label

Search

1128068

registered interest
date	22/05/2019
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Dementia
house id	2
legislature	25277 pref label House of Lords
question text	To ask Her Majesty's Government whether they plan to publish a national dementia strategy for beyond 2020; and if so, when.
tabling member printed	Baroness Crawley
uin	HL15917
answer	answer is ministerial correction date of answer 06/06/2019 answer text <p>We expect to publish a new dementia strategy for England for the period 2020 to 2025 early next year.</p> answering member printed Baroness Blackwood of North Oxford question first answered 06/06/2019 15:50:32 answering member 4019 label Biography information for Baroness Blackwood of North Oxford
tabling member	3386 label Biography information for Baroness Crawley

1128069

registered interest
date	22/05/2019
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Dementia
house id	2
legislature	25277 pref label House of Lords
question text	To ask Her Majesty's Government what progress they have made towards meeting the aims of the Prime Minister’s challenge on dementia.
tabling member printed	Baroness Crawley
uin	HL15918
answer	answer is ministerial correction date of answer 06/06/2019 answer text <p>We have committed to implement fully the Government’s <em>Challenge on Dementia 2020</em> strategy to make this country the best place in the world to live with dementia.</p><p> </p><p>Our recent review of progress tells us we are largely on track to meet our commitments to improve the lives of those living with dementia, their families and carers. The<em> Dementia 2020 Challenge: 2018 Review</em> <em>Phase 1</em> report is attached.</p><p> </p><p>Examples of progress we have made so far with our delivery partners include more than two thirds of people with dementia receiving a diagnosis, over 2.8 million people becoming Dementia Friends and 365 areas in England committing to being Dementia Friendly Communities. In the £250 million Dementia Discovery Fund we have the largest venture fund in the world aimed at discovering and developing novel pre-clinical therapies for dementia.</p> answering member printed Baroness Blackwood of North Oxford question first answered 06/06/2019 15:47:49 answering member 4019 label Biography information for Baroness Blackwood of North Oxford attachment 1 file name Dementia 2020 Challenge 2018 Review Phase 1.pdf title Dementia 2020 Challenge 2018 Review Phase 1
tabling member	3386 label Biography information for Baroness Crawley

1128090

registered interest
date	22/05/2019
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Health Services: Artificial Intelligence
house id	2
legislature	25277 pref label House of Lords
question text	To ask Her Majesty's Government what steps they are taking to invest in the development and use of artificial intelligence in the UK healthcare sector.
tabling member printed	Lord Taylor of Warwick
uin	HL15939
answer	answer is ministerial correction date of answer 06/06/2019 answer text <p>The Department of Health and Social Care is leading on the Prime Minister’s Mission to “Use data, Artificial Intelligence and innovation to transform the prevention, early diagnosis and treatment of chronic diseases by 2030.” We hope that as we work towards this overall goal, we can ensure that: patients experience better care, clinicians deliver better care, commissioners are better able to commission data-driven technologies and the United Kingdom is a great place to do business in artificial intelligence (AI) for health and care.</p><p>We are working in partnership with organisations across the National Health Service, the Department for Business, Energy and Industrial Strategy, Office for Life Sciences, Office for Artificial Intelligence and Better Regulation Executive to engage with businesses in the sector so that we benefit from the potential for AI to improve care, deliver better outcomes, contribute to efficiency in the health and care system and contribute to the wider economy. In September 2018, we published the Code of Conduct for Data-Driven Health and Care Technology, which clearly sets out the behaviours we expect from those developing AI and related technologies. The Code was updated in February 2019 based on feedback, including from industry partners, and we are working with them to develop case studies showing good practice in complying with the Code. We are also developing tools to help businesses comply with the Code of Conduct.</p><p>The Office for Artificial Intelligence and UK Research and Innovation have announced centres for doctoral training in AI-enabled healthcare across the UK.</p><p>The Office for Life Sciences has established five Centres of Excellence in digital pathology and radiology with AI, supported by an initial £50 million Industrial Strategy Challenge Fund investment and a further £50 million of scale up funding from the Department of Health and Social Care. The centres are working with NHS and industry partners, including innovative small and medium-sized enterprises, to develop pioneering AI-enabled pathology and radiology tools.</p><p>In addition we are also working closely with Health Education England as they follow through on the recommendations made by the Topol Review <em>Preparing the healthcare workforce to deliver the digital future</em>.</p><p>In March 2019, the National Institute for Health and Care Excellence published its <em>Evidence Standards Framework for Digital Health Technologies</em>, outlining the evidence required by businesses to demonstrate the effectiveness and economic impact of digital health technologies.</p><p>Taken together these steps, and others, will ensure there is a clear framework for the development and use of AI in the healthcare sector including the skills, a clear path to market, and a rigorous process for ensuring the safety, efficacy and ethics of the tools developed, deployed and used.</p><p> </p> answering member printed Baroness Blackwood of North Oxford question first answered 06/06/2019 15:40:44 answering member 4019 label Biography information for Baroness Blackwood of North Oxford
tabling member	1796 label Biography information for Lord Taylor of Warwick

1128094

registered interest
date	22/05/2019
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Malnutrition: Screening
house id	2
legislature	25277 pref label House of Lords
question text	To ask Her Majesty's Government what steps they are taking to offer screening for malnutrition at GP surgeries and pharmacies in England.
tabling member printed	Baroness Thomas of Winchester
uin	HL15943
answer	answer is ministerial correction date of answer 06/06/2019 answer text <p>The UK National Screening Committee (UK NSC) advises ministers and the National Health Service in all four countries about all aspects of screening policy and supports implementation. Using research evidence, pilot programmes and economic evaluation, it assesses the evidence for programmes against a set of internationally recognised criteria.</p><p> </p><p>The UK NSC has not reviewed the evidence to screen for malnutrition, however the Committee welcomes new topic proposals via its annual call for topics which opens each year from September to December.</p><p> </p><p>The UK NSC has published its evidence review process online on GOV.UK, which includes how to submit a new topic proposal.</p> answering member printed Baroness Blackwood of North Oxford question first answered 06/06/2019 15:41:32 answering member 4019 label Biography information for Baroness Blackwood of North Oxford
tabling member	3785 label Biography information for Baroness Thomas of Winchester

1128095

registered interest
date	22/05/2019
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Nutrition
house id	2
legislature	25277 pref label House of Lords
question text	To ask Her Majesty's Government what assessment they have made of appointing a clinical lead for nutrition for the NHS in England.
tabling member printed	Baroness Thomas of Winchester
uin	HL15944
answer	answer is ministerial correction date of answer 06/06/2019 answer text <p>NHS England and NHS Improvement have a lead Nutrition and Hydration Specialist in Quality Improvement. Their work focusses on building collaboratives to improve nutrition and hydration within providers.</p><p> </p><p>In addition, Public Health England’s (PHE) Chief Nutritionist provides leadership and strategic oversight on key priority areas of diet, nutrition, obesity and physical activity to PHE, the Department and other Government departments.</p> answering member printed Baroness Blackwood of North Oxford question first answered 06/06/2019 15:39:31 answering member 4019 label Biography information for Baroness Blackwood of North Oxford
tabling member	3785 label Biography information for Baroness Thomas of Winchester

1127749

registered interest
date	21/05/2019
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	NHS: BioMarin
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, what assessment his Department has made of the progress of talks on procuring medicines between the NHS and Bio Marin.
tabling member constituency	Gloucester
tabling member printed	Richard Graham
uin	256971
answer	answer is ministerial correction date of answer 30/05/2019 answer text <p>We have made no such assessment. Discussions about commercial agreements for medicines are rightly held between NHS England as an independent body and the manufacturer concerned. The Department plays no role in such discussions.</p> answering member constituency South Ribble answering member printed Seema Kennedy question first answered 30/05/2019 10:48:36 answering member 4455 label Biography information for Seema Kennedy
tabling member	3990 label Biography information for Richard Graham

1127754

registered interest
date	21/05/2019
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Blood Diseases: Health Services
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, what his timescale is for (a) implementing and (b) completing NHS England’s planned restructuring of haemoglobinopathy services; and if he will make a statement.
tabling member constituency	Kingston upon Hull North
tabling member printed	Diana Johnson
uin	256972
answer	answer is ministerial correction date of answer 04/06/2019 answer text <p>It is anticipated that NHS England’s new model for specialised haemoglobinopathy services will be in place by early 2020. The new model is designed to improve access to specialist advice and care for patients, irrespective of where they live.</p><p>As part of the new service, NHS England is establishing a National Haemoglobinopathy Panel to provide national multidisciplinary oversight. Patients with complex needs, wherever they live, will be able to be referred to the Panel for expert advice on new treatments and approaches to care. The national service specification will also include guidance for the 13 new born bloodspot screening programme laboratories to refer infants found to be positive for sickle cell disease to the 10 new specialised haemoglobinopathy teams. Whilst NHS England commissions the specialised aspect of haemoglobinopathy care, haemoglobinopathy coordinating centres will be encouraged to link with and support community-based services provided through primary care or community teams based within haemoglobinopathy teams.</p><p>The service specifications for the new specialised haemoglobinopathy teams and the haemoglobinopathy coordinating centres are due to be established in the next month and the associated impact assessment will be published as part of the suite of documents. The equality impact assessment indicates that it will advance the promotion of equality and support the reduction of health inequalities. For example, patients with thalassemia and sickle cell conditions will have equitable access to high quality specialist care and support within specialised commissioned centres irrespective of where in the country they live.</p><p>Hospital Episode Statistics data is attached, showing finished admission episodes with a primary and a primary or secondary diagnosis of sickle cell disorders by NHS England region of residence and Index of Multiple Deprivation decile in the year 2017-18.</p> answering member constituency South Ribble answering member printed Seema Kennedy grouped question UIN 256973 256974 257011 question first answered 04/06/2019 16:13:21 answering member 4455 label Biography information for Seema Kennedy attachment 1 file name Data Table for Combined Diana Johnson PQs (257011) formatted.xlsx title FAE sickle cell NHS England table
tabling member	1533 label Biography information for Dame Diana Johnson

1127755

registered interest
date	21/05/2019
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Sickle Cell Diseases: Health Services
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, what assessment he has made of the effect of NHS England’s planned restructuring of haemoglobinopathy services on (a) equitable access to services, (b) access to the most effective treatments, (c) access to highly specialised care and (d) quality of care in community-based settings for patients with sickle cell disease.
tabling member constituency	Kingston upon Hull North
tabling member printed	Diana Johnson
uin	256973
answer	answer is ministerial correction date of answer 04/06/2019 answer text <p>It is anticipated that NHS England’s new model for specialised haemoglobinopathy services will be in place by early 2020. The new model is designed to improve access to specialist advice and care for patients, irrespective of where they live.</p><p>As part of the new service, NHS England is establishing a National Haemoglobinopathy Panel to provide national multidisciplinary oversight. Patients with complex needs, wherever they live, will be able to be referred to the Panel for expert advice on new treatments and approaches to care. The national service specification will also include guidance for the 13 new born bloodspot screening programme laboratories to refer infants found to be positive for sickle cell disease to the 10 new specialised haemoglobinopathy teams. Whilst NHS England commissions the specialised aspect of haemoglobinopathy care, haemoglobinopathy coordinating centres will be encouraged to link with and support community-based services provided through primary care or community teams based within haemoglobinopathy teams.</p><p>The service specifications for the new specialised haemoglobinopathy teams and the haemoglobinopathy coordinating centres are due to be established in the next month and the associated impact assessment will be published as part of the suite of documents. The equality impact assessment indicates that it will advance the promotion of equality and support the reduction of health inequalities. For example, patients with thalassemia and sickle cell conditions will have equitable access to high quality specialist care and support within specialised commissioned centres irrespective of where in the country they live.</p><p>Hospital Episode Statistics data is attached, showing finished admission episodes with a primary and a primary or secondary diagnosis of sickle cell disorders by NHS England region of residence and Index of Multiple Deprivation decile in the year 2017-18.</p> answering member constituency South Ribble answering member printed Seema Kennedy grouped question UIN 256972 256974 257011 question first answered 04/06/2019 16:13:21 answering member 4455 label Biography information for Seema Kennedy attachment 1 file name Data Table for Combined Diana Johnson PQs (257011) formatted.xlsx title FAE sickle cell NHS England table
tabling member	1533 label Biography information for Dame Diana Johnson

1127756

registered interest
date	21/05/2019
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Sickle Cell Diseases: Health Services
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, if he will publish impact assessments of the potential effects of NHS England’s planned restructuring of haemoglobinopathy services on treatment of (a) all haemoglobinopathies and (b) sickle cell disease.
tabling member constituency	Kingston upon Hull North
tabling member printed	Diana Johnson
uin	256974
answer	answer is ministerial correction date of answer 04/06/2019 answer text <p>It is anticipated that NHS England’s new model for specialised haemoglobinopathy services will be in place by early 2020. The new model is designed to improve access to specialist advice and care for patients, irrespective of where they live.</p><p>As part of the new service, NHS England is establishing a National Haemoglobinopathy Panel to provide national multidisciplinary oversight. Patients with complex needs, wherever they live, will be able to be referred to the Panel for expert advice on new treatments and approaches to care. The national service specification will also include guidance for the 13 new born bloodspot screening programme laboratories to refer infants found to be positive for sickle cell disease to the 10 new specialised haemoglobinopathy teams. Whilst NHS England commissions the specialised aspect of haemoglobinopathy care, haemoglobinopathy coordinating centres will be encouraged to link with and support community-based services provided through primary care or community teams based within haemoglobinopathy teams.</p><p>The service specifications for the new specialised haemoglobinopathy teams and the haemoglobinopathy coordinating centres are due to be established in the next month and the associated impact assessment will be published as part of the suite of documents. The equality impact assessment indicates that it will advance the promotion of equality and support the reduction of health inequalities. For example, patients with thalassemia and sickle cell conditions will have equitable access to high quality specialist care and support within specialised commissioned centres irrespective of where in the country they live.</p><p>Hospital Episode Statistics data is attached, showing finished admission episodes with a primary and a primary or secondary diagnosis of sickle cell disorders by NHS England region of residence and Index of Multiple Deprivation decile in the year 2017-18.</p> answering member constituency South Ribble answering member printed Seema Kennedy grouped question UIN 256972 256973 257011 question first answered 04/06/2019 16:13:21 answering member 4455 label Biography information for Seema Kennedy attachment 1 file name Data Table for Combined Diana Johnson PQs (257011) formatted.xlsx title FAE sickle cell NHS England table
tabling member	1533 label Biography information for Dame Diana Johnson

1127772

registered interest
date	21/05/2019
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Voluntary Scheme for Branded Medicines Pricing and Access
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, whether the review of the methods for the NICE Technology Appraisal Programme referred to in the 2019 voluntary scheme for branded medicines pricing and access will include support for earlier patient access to innovative medicines.
tabling member constituency	Bolton West
tabling member printed	Chris Green
uin	257056
answer	answer is ministerial correction date of answer 30/05/2019 answer text <p>The National Institute for Health and Care Excellence (NICE) is in the process of scoping the review of the methods for technology appraisal and highly specialised technologies evaluations. Scoping will involve patient organisations and other relevant stakeholders, including industry. The Voluntary Scheme for Branded Medicines Pricing and Access sets out the Department’s expectation that that any future changes to NICE methods and processes would support faster adoption of the most clinically and cost effective medicines. Additional detail and more information will be made available on the NICE website in due course.</p><p>The 2019 Voluntary Scheme also states that NICE will adopt the principle of appraisal timelines for non-oncology treatments matching the faster timescales for oncology treatments, subject to the evidence base for the product being sufficiently developed to enable a NICE appraisal with the same level of rigour and certainty as would be expected currently.</p> answering member constituency South Ribble answering member printed Seema Kennedy question first answered 30/05/2019 10:52:06 answering member 4455 label Biography information for Seema Kennedy
tabling member	4398 label Biography information for Chris Green